SonoThera

SonoThera is a private, preclinical-stage biotech founded in 2020, pioneering a novel non-viral gene delivery platform based on therapeutic ultrasound. The company's core technology, Ultrasound-Mediated Delivery (UMD), seeks to precisely target genetic medicines to specific organs, deliver large DNA/RNA constructs, and allow for redosing, addressing key challenges in the field. With a $125M Series B financing secured in early 2026, SonoThera is advancing a pipeline focused on genetic disorders such as Duchenne Muscular Dystrophy, Hemophilia A, and X-Linked Alport Syndrome, positioning itself as a potential disruptor in targeted genetic medicine.

Ultrasound-Mediated Delivery (UMD): A proprietary, non-invasive platform using focused ultrasound waves to enable targeted, redosable delivery of large DNA/RNA genetic payloads to specific organs without viral vectors.

SonoThera competes with developers of viral vectors (e.g., AAV companies like Sarepta, Pfizer) and non-viral delivery technologies (e.g., LNP developers, other physical delivery methods). Its key differentiators are its non-invasive, organ-targeted, redosable approach and capacity for unlimited payload size, which are significant limitations for current AAV and LNP platforms.